about
A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous LeishmaniasisMucosal leishmaniasis: an underestimated presentation of a neglected diseaseInnate immunity against Leishmania infectionsCytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasisPlasticity of the Leishmania genome leading to gene copy number variations and drug resistanceSpecies-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1BluePort: a platform to study the eosinophilic response of mice to the bite of a vector of Leishmania parasites, Lutzomyia longipalpis sand fliesThe evolution of trypanosomatid taxonomy.Applicability of kDNA-PCR for routine diagnosis of American tegumentary leishmaniasis in a tertiary reference hospitalNon-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology.The impact of human immunodeficiency virus (HIV) co-infection on the economic burden of cutaneous leishmaniasis (CL) in Brazil and potential value of new CL drug treatmentsA species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.Leishmanicidal evaluation of tetrahydroprotoberberine and spirocyclic erythrina-alkaloids.Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning TravelersPhosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Differential Gene Expression and Infection Profiles of Cutaneous and Mucosal Leishmania braziliensis Isolates from the Same Patient.Comparative genomic analysis of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis.Visceral leishmaniasis in a patient with cutaneous lesions, negative Leishman-Donovan bodies and immunological test: A case report.Lip leishmaniasis: a case series with molecular identification and literature review.Development of loop-mediated isothermal amplification (LAMP) for simple detection of Leishmania infectionQuantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.New world cutaneous leishmaniasis treated with intralesional injection of pentavalent antimonySimultaneous infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian patient with cutaneous leishmaniasis.Isolated laryngeal leishmaniasis in immunocompetent patients: an underdiagnosed disease.Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis.The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.Leishmaniasis: clinical syndromes and treatment.Autophagy in trypanosomatids.Toll-like receptors in leishmania infections: guardians or promoters?Auricular cutaneous leishmaniasis mimicking neoplastic disease.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.Leishmaniasis: diagnostic issues in Europe.Unraveling the genetic diversity and phylogeny of Leishmania RNA virus 1 strains of infected Leishmania isolates circulating in French GuianaTropical Skin Diseases in Children: A Review-Part II.Efficiency of noninvasive sampling methods (swab) together with Polymerase Chain Reaction (PCR) for diagnosing American Tegumentary Leishmaniasis.Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomesConventional formulations and emerging delivery systems for the topical treatment of Cutaneous Leishmaniasis.In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
P2860
Q26786195-0E542878-5E5F-4705-ADEC-BF9F0F11F6C3Q26998036-B903B6F5-6E60-4952-B3C5-08F91F1CD20CQ27010187-807FA45C-5CA4-407B-AE93-329937276D09Q27334358-B394821E-5258-4372-8D74-B11C935872CEQ28074697-91A27115-DA76-470C-87BA-F22D4C91FFF7Q28543678-3AD2F9F0-2BBA-4F2E-8E5E-3C542C3BDE16Q28748688-2FB19DFE-BC38-451A-8284-EF310F45026EQ33776260-A35E6987-9B31-4089-BEA5-434F4223A466Q33926519-33C4931A-96B8-4BB7-A98C-FD9BE82617E7Q34064432-90281B25-276B-49E6-AA4F-B08CC2F11E54Q34138468-E712439F-6561-457D-A2AF-E77F6DA9331AQ34422191-5F050B45-5A14-46D6-8F67-A61A90D6EB3DQ35164147-599F6AE3-953D-45E3-A998-22280F69CF03Q35180338-3C0CBF41-1C8C-407B-AA7A-40836F672A28Q35189546-DA69115C-6D5D-4284-9991-6FC90807573EQ35198753-C79A5A15-346C-490A-934E-D7E2E80F0D82Q35772188-EADD9351-9D10-4E0C-AB9A-CE783C88E3B4Q35780780-F33E29BB-8978-46ED-B1DB-95FCEFC2419FQ36196585-F2FABD22-1F26-4FEF-8570-8E96CF2CDC60Q36260068-D9CE5107-7BBB-4F5A-AAD6-06A0B7EE1EF1Q36292430-CC21FB62-C8AC-4C2C-9DAA-99D8347780CAQ36455737-6C87E1F4-4E03-43CD-ABCF-532187D6210BQ36640553-F15376BE-072A-4B23-87DD-FB8B52610450Q36743902-6818793B-10EC-4CEE-9D25-638F59B7116DQ36805012-AC5E9E65-6905-403C-98C9-FF4361B6307BQ37026407-E0DC1B3E-ED7E-4E0A-8335-574616C5EDECQ37045346-9AC3FE74-1061-412C-B9B1-B7335A6F24A8Q37147622-427074CC-E377-4B6F-BA5F-29B64AE0AD88Q37406305-829214F8-33D6-46EC-8783-69FC58621FF7Q37512274-71C4EEC7-32B3-4833-B811-2BB5D727DA7DQ38004493-381FDFAA-B7CC-4288-B6C1-3ABAD6F35DF7Q38019175-DB5A7ACF-1588-41A6-82DB-78C0F5AE2EBCQ38195310-70A9AA65-F0B5-40D8-BC10-5141168D312FQ38554579-5A9C44F6-119C-4873-B308-E134414F768BQ38675651-583E8FF4-0568-4542-A83D-E182CCB5DE65Q38796806-276D2CE3-66EA-4AC3-A670-BF9DC562C476Q38914232-59F7B675-F2F7-49F6-8F8B-23208A48C41DQ38973386-17B48871-69B1-45B9-866F-13F11AC21258Q38995479-641D6190-B7FB-472E-82D5-7714F6F5DD5CQ39183293-38665201-49B7-4F15-960E-004F032DFDB9
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Cutaneous and mucocutaneous leishmaniasis.
@en
Cutaneous and mucocutaneous leishmaniasis.
@nl
type
label
Cutaneous and mucocutaneous leishmaniasis.
@en
Cutaneous and mucocutaneous leishmaniasis.
@nl
prefLabel
Cutaneous and mucocutaneous leishmaniasis.
@en
Cutaneous and mucocutaneous leishmaniasis.
@nl
P2860
P1433
P1476
Cutaneous and mucocutaneous leishmaniasis.
@en
P2093
Consuelo V David
Noah Craft
P2860
P304
P356
10.1111/J.1529-8019.2009.01272.X
P577
2009-11-01T00:00:00Z